Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
J Dermatolog Treat
; 32(2): 203-211, 2021 Mar.
Article
in En
| MEDLINE
| ID: mdl-31769703
ABSTRACT
OBJECTIVES:
To compare treatment patterns and costs among psoriasis patients with and without metabolic conditions newly initiating a biologic or apremilast.METHODS:
Adult patients included had ≥1 prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast between 01/01/2015 and 08/31/2018 (date of first prescription was index date) and no index drug use in the 12-months pre-index, and continuous enrollment in the 12-month pre-index and 24-month post-index periods. Patients were divided into mutually exclusive treatment cohorts and stratified by their pre-index metabolic condition status. Treatment patterns (adherence, non-persistence, switching, discontinuation, use of combination therapy, and re-initiation) and healthcare costs were compared.RESULTS:
Overall, 7773 patients were included; 47.5-56.7% had a metabolic condition. Except for the apremilast group, patients with metabolic conditions had higher discontinuation (secukinumab 50.6% vs. 43.7%; adalimumab* 53.9% vs. 48.7%; ustekinumab* 41.9% vs. 35.1%; etanercept 42.8% vs. 41.2%; apremilast 43.1% vs. 46.1%) and switching (secukinumab 48.1% vs. 41.2%; adalimumab* 47.8% vs. 41.9%; ustekinumab* 34.5% vs. 25.3%; etanercept* 53.6% vs. 51.5%; apremilast 45.8% vs. 44.6%) than patients without (*p < .05). Patients with metabolic conditions incurred significantly higher costs.CONCLUSION:
Many psoriasis patients initiating biologics or apremilast had metabolic conditions. These patients had higher discontinuation and switching, and significantly higher healthcare costs.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Health Care Costs
/
Dermatologic Agents
Type of study:
Health_economic_evaluation
/
Observational_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Dermatolog Treat
Journal subject:
DERMATOLOGIA
Year:
2021
Document type:
Article
Affiliation country:
Estados Unidos